Hot Shipping Stocks To Invest In Right Now

ST. LOUIS, Mo. (AP) — Nestle Purina PetCare Co. said Friday that it is recalling some of its dog food because of a possible salmonella risk.

The recall is limited to 3.5-pound bags of its Purina ONE beyOnd Our White Meat Chicken & Whole Barley Recipe Adult Dry Dog Food with the sell by date of “Oct. 2014” and unit UPC code of “2014 31071083 17800 12679.”

One bag of the product was found to be contaminated with salmonella and no illnesses have been reported, Nestle Purina PetCare said.

Pets with salmonella may have decreased appetite, fever and abdominal pain.

The company advised customers to throw the food out and contact a veterinarian. Human contamination is also possible and can result in nausea, vomiting, diarrhea and more serious problems such as muscle pain and eye irritation, the company said.

Customers can call Nestle Purina PetCare, at 800-473-8546, if they have questions or want a refund.

Nestle Purina PetCare is a unit of Nestle, the Switzerland-based food and drinks company.

Hot Shipping Stocks To Invest In Right Now: United Insurance Holdings Corp (UIHC)

United Insurance Holdings Corp. (UIHC), incorporated on May 22, 2007, is a holding company for United Property and Casualty Insurance Company and its affiliated companies. Its business is conducted principally through four wholly-owned subsidiaries, including United Property and Casualty Insurance Company (UPC), which writes insurance policies; United Insurance Management, L.C. (UIM), the managing general agent that manages substantially all aspects of UPC’s business, Skyway Claims Services, LLC (SCS), a claims adjusting company that provides services to UPC; and UPC Re. UPC Re provides reinsurance protection to UPC.

The Company offers standardized policies for a range of exposures, and its policies include coverage options for standard single-family homeowners, tenants (renters), and condominium unit owners. It also writes flood policies. The Company has authorization to write a commercial line of business in Florida that includes auto and multi-peril coverag e but the Company does not write commercial business. The Company offers standardized policies for a broad range of exposures, and its policies include coverage options for standard single-family homeowners, tenants (renters), and condominium unit owners.

The Company competes with Citizens Property Insurance Corporation, State Farm Florida Insurance Company, Universal Property & Casualty Insurance Company, St. Johns Insurance Company, Inc., United Services Automobile Association, American Coastal Insurance Company, Florida Peninsula Insurance Company, Security First Insurance Company, Homeowners Choice Property & Casualty Insurance Company, Inc., United Property & Casualty Insurance Company, Tower Hill Prime Insurance Company, Federal Insurance Company, USAA Casualty Insurance Company, Castle Key Insurance Company, American Integrity Insurance Company of Florida, Tower Hill Signature Insurance Company, ASI Assurance Corp., Tower Hill Preferred Insurance Company, Chartis Property Casualty Company and Universal Insurance C! ompany of North America.

Advisors’ Opinion:

  • [By Louis Navellier]

    United Insurance Holdings (UIHC) is a great example of a best of the best stock that should climb the wall of worry this summer. Writing homeowners and flood insurance might not be the most exciting business sin the word but the fundamentals of this company are really exciting.

Hot Shipping Stocks To Invest In Right Now: Lpath Inc (LPTN)

Lpath, Inc. (Lpath), incorporated on September 18, 2002, is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Company’s program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma.

Lpath’s third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.

Advisors’ Opinion:

  • [By Lauren Pollock]

    Lpath Inc.(LPTN) said it is no longer actively seeking to reacquire exclusive rights to its leading product candidate from Pfizer Inc.(PFE), saying the pharmaceutical giant informed the company that its offers weren’t competitive. The biotechnology company in October had warned that Pfizer might may divest itself of its exclusive option to co-develop the smaller firm’s leading product candidate–known as iSONEP.

  • [By Lauren Pollock]

    Biotechnology company Lpath Inc.(LPTN) warned Pfizer Inc.(PFE) may divest itself of its exclusive option to co-develop the smaller firm’s leading product candidate. Lpath’s stock fell.

Hot Shipping Stocks To Invest In Right Now: Computershare Ltd (CPU)

Computershare Limited is an Australia-based company. The Company is engaged in the operation of investor services, plan services, communication services, business services, shareholder relationship management services and technology services. The Company operates in six geographical segments: Asia, Australia, and New Zealand, Canada, Continental Europe, United Kingdom, Channel Islands, Ireland & Africa (UCIA) and the United States. In addition, technology and other segment comprise the provision of software specializing in share registry, employee plans and financial services globally, as well as the production and distribution of interactive meeting products. In December 2013, Computershare Ltd completed the acquisition of the Olympia Corporate and Shareholder Services assets (OCSS) from Olympia Financial Group Inc. Advisors’ Opinion:

  • [By Toshiro Hasegawa]

    Leighton dropped 6 percent to A$16.24 in Sydney as profit missed analyst estimates amid a slump in mining industry demand. Computershare Ltd. (CPU) sank 6.3 percent to A$9.75 in Sydney, the most in three years, after the share-registry firm reported profit fell.

Hot Shipping Stocks To Invest In Right Now: Plexus Corp.(PLXS)

Plexus Corp., together with its subsidiaries, provides electronic manufacturing services to original equipment manufacturers and other technology companies. The company offers product development and design services, including program management, feasibility studies, product conceptualization, specification development, circuit design, field programmable gate array design, printed circuit board layout, embedded software design, mechanical design, development of test specifications, and product verification testing. It also provides value-added services, such as engineering change-order management, cost reduction redesign, component obsolescence management, product feature expansion, test enhancement, and component re-sourcing. In addition, the company offers prototyping and new product introduction services comprising assembly of prototype products, materials management, analysis of the manufacturability and testability of a design, test implementation, and pilot productio n. Further, it provides test equipment development; material sourcing and procurement; agile manufacturing; fulfillment and logistic; after-market support; and regulatory requirements services. The company serves the wireline/networking, wireless infrastructure, medical, industrial/commercial, and defense/security/aerospace markets in the United States, Malaysia, China, the United Kingdom, Mexico, and Romania. Plexus Corp. was founded in 1979 and is headquartered in Neenah, Wisconsin.

Advisors’ Opinion:

  • [By Seth Jayson]

    Plexus (Nasdaq: PLXS  ) reported earnings on July 17. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended June 29 (Q3), Plexus beat slightly on revenues and beat expectations on earnings per share.

  • [By Evan Niu, CFA]

    What: Shares of Plexus (NASDAQ: PLXS  ) have jumped today by as much as 13% after the company reported earnings results.

    So what: Revenue in the fiscal third quarter totaled $571.9 million, well ahead of the Street consensus of $565 million. Earnings per share were $0.68, similarly topping expectations of just $0.58 per share. CEO Dean Foate said the strong results were driven by the networking and communications as well as the health care and life sciences sectors.

Hot Shipping Stocks To Invest In Right Now: Credit Suisse Group AG (CSGN.VX)

Credit Suisse Group AG is a Switzerland-based holding company engaged in private banking, investment banking and asset management areas. It operates through four divisions: Private Banking, which consists of the Wealth Management Clients and Corporate & Institutional Clients business; Investment Banking, provides a range of financial products and services, with a focus on client-driven, flow-based and capital-efficient businesses; Asset Management, offers a range of asset class products, including alternative investments, and multi-asset class solutions, including equities and fixed income products, and Shared Services, which provides centralized corporate services and business support for the Company’s divisions. Advisors’ Opinion:

  • [By Dan Strumpf]

    As big macroeconomic headlines recede, ETFs are falling out of favor. ETF volumes have dipped this year to about 16.5% of total equity volumes, down from 16.7% in 2013, according to analysts at Credit Suisse(CSGN.VX) Trading Strategy. The data suggest that investors are increasingly favoring trades in individual stocks.

Hot Shipping Stocks To Invest In Right Now: Astellas Pharma Inc (ALPMY.PK)

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, chronic hepatitis C, irritable bowel syndrome, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, agrypnia, atopic dermatitis and other diseases. Advisors’ Opinion:

  • [By Henry Kawabe]

    Seattle Genetic is currently collaborating on 22 different ADC drug trials in various stages of testing with twelve different pharmaceutical companies, including nine with Genentech (RHHBY.OB), two with AbbVie (ABBV), two with Agensys (ALPMY.PK), and one with Pfizer (PFE). To date, these ADC collaborations have generated more than $225 million for Seattle Genetics and have the potential to generate more than $3.5 billion in milestone payments plus royalties.

Hot Shipping Stocks To Invest In Right Now: AEterna Zentaris Inc.(AEZS)

Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company?s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.

Advisors’ Opinion:

  • [By Eric Volkman]

    Aeterna Zentaris (NASDAQ: AEZS  ) has made a significant change in its executive suite and boardroom. David Dodd is now the company’s chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.

  • [By Sean Williams]

    What’s coming down the pipeline
    As we saw with the current treatment options, the endometrial cancer pipeline isn’t filled with a lot of choices, but they are at least more encouraging than the standard care treatments we’ve seen over the past three decades.

    Avastin: Surprise: It’s Roche’s (NASDAQOTH: RHHBY  ) wonder drug yet again! Roche’s Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don’t be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results.  AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS  ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthetic peptide carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.

    Your best investment
    With very few investable options to choose from, since many of these treatments are off patent as they’re decades old, I’m going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons.

Hot Shipping Stocks To Invest In Right Now: Spdr S&P Homebuilders Etf (XHB)

SPDR S&P Homebuilders ETF (the Fund) seeks to replicate as closely as possible, before expenses, the performance of the S&P Homebuilders Select Industry Index (the Index). To accomplish this, the Fund utilizes a passive or indexing approach and attempts to approximate the investment performance of its Index, by investing in a portfolio of stocks intended to replicate the Index.

The S&P Homebuilders Select Industry Index seeks to provide a representation of the homebuilders’ sub-industry portion of the S&P Total Market Index. The S&P TMI tracks all the United States common stocks regularly traded on the NYSE, American Stock Exchange, NASDAQ National Market and NASDAQ Small Cap Exchanges. The Homebuilders Index is an equal weighted market cap index.

Advisors’ Opinion:

  • [By Jon C. Ogg]

    1. The U.S. economy grows 3% as housing starts surpass one million and private employment hits an all-time high – All time high on private employment? 1 million housing starts?

    Homebuilder ETF: SPDR S&P Homebuilders ETF (NYSEArca: XHB) as it is tied to homebuilders and building products rather than including other sectors that only overlap in building. At $32.57, its 52-week range is 426.94 to $33.38. Housing Starts were always well over 1 million on an annualized basis each month before the recession, but they only reached that in two months of 2013 (St. Louis Fed data).

    2. 10-Year Treasury yields move toward 3.5% as the Federal Reserve completes tapering and holds short-term rate near zero – This may sound bad, but it is actually good and fits in line with rates not rising too much. Keep in mind that the 10-year Treasury is at 2.94% now and ended at 3.03% on the last day of 2013. Elsewhere on the yield curve, Doll sees many parts of the fixed income market to end 2014 with negative total rates of return.

  • [By John Maxfield]

    Meanwhile, housing is feeling the effects via higher mortgage rates. For portions of last year, a 30-year conventional mortgage carried an interest rate of less than 3.5%. Since the Fed’s announcements, the same rate has climbed back to more than 4%. This is sending shivers through homebuilders’ stocks, as the net effect is to make homes more expensive. The SPDR S&P Homebuilders (NYSEMKT: XHB  ) ETF, which tracks the housing sector, is down almost 9% since May 22.